department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

C4 Therapeutics, Inc. ($CCCC) · pharmadog

PUBLIC COMPANY

$CCCCC4 Therapeutics, Inc.

Watertown, MA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 21Unknown

Anaplastic Large Cell Lymphoma (ALCL)

1. INDICATIONS AND USAGE UNLOXCYT is indicated for the tr…

Programmed cell death 1 ligand 1

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view C4 Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$CCCC

SEC CIK

0001662579

country

US

source

sec_tickers

top tags

DLBCL1 Oncology1

mentioned in

0news items

entity-linker matched

Active trials

phase1A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjectsrecruitingn=60
phase1Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myelomaactive not recruitingn=224
phase2A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myelomarecruitingn=100
phase1A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumorscompletedn=89
phase1A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumorsterminatedn=49

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

SEC EDGAR · openFDA

last refreshed 4m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$CCCC

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Apr 1, 26grantGROGAN DONNA ROY · director5,370 sh
Apr 1, 26grantAnderson Kenneth Carl · director4,259 sh
Feb 15, 26tax coverHirsch Andrew · President & CEO9,057 sh
Feb 15, 26option exerciseHirsch Andrew · President & CEO20,400 sh
Feb 14, 26tax coverHirsch Andrew · President & CEO39,154 sh
Feb 14, 26tax coverREYNO LEONARD · Chief Medical Officer16,579 sh